Quick Overview
Tirzepatide is a dual incretin receptor agonist targeting both GLP-1 and GIP receptors, designed to modulate glucose homeostasis, insulin secretion, and appetite signalling within metabolic research models.

Full Research Overview
Tirzepatide is a synthetic peptide engineered to simultaneously activate GLP-1 and GIP receptors, providing a dual-pathway approach to metabolic regulation
GLP-1 receptor activation contributes to reduced gastric emptying and increased satiety signalling through central nervous system pathways. GIP receptor engagement enhances insulin secretion in a glucose-dependent manner and may influence adipocyte metabolism and lipid storage mechanisms.




